key: cord-0255396-dwlii5w6
authors: Bliden, K. P.; Liu, T.; Sreedhar, D.; Kost, J.; Hsiung, J.; Zhao, S.; Shan, D.; Usman, A.; Walia, N.; Cho, A.; Jerjian, C.; Tantry, U. S.; Gurbel, P. A.; Tang, M.; Dai, H.
title: Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
date: 2021-07-02
journal: nan
DOI: 10.1101/2021.06.28.21259338
sha: 0a1b82c91b160fccbd9874970aed6095ad2709fc
doc_id: 255396
cord_uid: dwlii5w6

Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between vaccines. Here we performed a prospective pilot study of 71 previously COVID-19 free subjects upon receiving both doses of either the Pfizer (n = 54) or Moderna (n = 17) mRNA vaccine. Anti-spike protein receptor binding domain (RBD) IgG antibodies were measured longitudinally using a qualitative finger stick MidaSpot rapid test at the point-of-care for initial screening and a quantitative dry blood spot-based pGOLD laboratory test over ~ four months post-vaccination. The average anti-RBD IgG antibody levels peaked at ~ two weeks after the second dose vaccine and declined thereafter, while antibody avidity increased, suggesting antibody maturation. Moderna vaccine recipients compared to Pfizer vaccine recipients exhibited higher side effect severity, higher peak anti-RBD IgG antibody levels, and higher avidity up to the 90 days period. Differences in antibody levels diminished at ~ 120 days post-vaccination, in line with the similar efficacy observed in the two vaccines. The MidaSpot rapid test detected 100% anti-SARS-CoV-2 RBD positivity for fully vaccinated subjects in both Pfizer and Moderna cohorts post full vaccination but turned negative greater than 90 days post-vaccination for 5.4% of subjects in the Pfizer cohort, whose quantitative anti-IgG were near the minimum levels of the group. Immune responses were found to vary greatly among vaccinees. Personalized longitudinal monitoring of antibodies could be necessary to assessing the immunity duration of vaccinated individuals.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents a great challenge to global health and has claimed millions of lives worldwide. Moreover, until herd immunity is successfully induced in a large population throughout the world, SARS-CoV-2 infections are likely to become endemic, leading to further loss of life. In response, multiple vaccine candidates based on RNA and DNA technologies, inactivated viruses, and other approaches have been rapidly developed 1-3 . Especially in the United States, two messenger RNA 19, 20 . Neutralization assays [21] [22] [23] [24] [25] have been developed to quantify antibodies directly responsible for neutralizing viruses, and a strong correlation between neutralizing antibody titers with antibody levels against spike protein/RBD in COVID-19 patients has been reported 20,26-34 . In addition, antibody avidity measures the strength of antibody binding to viral antigens, shedding light on antibody maturation, and is potentially useful for assessing vaccine efficacy [35] [36] [37] [38] [39] [40] . Therefore, it is important to measure both IgG levels and avidity to assess not only antibody quantity but also viral antigen binding ability post-infection or post-vaccination over time. On the other hand, reliable and inexpensive tests could be implemented in hospitals, clinics, various point-of-care (POC) sites, and even at home for frontline qualitative antibody detection to assess immune responses to COVID-19 infection or vaccination.

The primary objectives of this study were to longitudinally assess the immune responses to the Pfizer and Moderna mRNA vaccines by measuring anti-RBD IgG antibody levels and IgG avidity using the pGOLD™ assay. We also compared antibody production between the Pfizer and Moderna vaccines, and the relation to severity of post-vaccination reactions. We reported the results of longitudinal POC rapid testing of antibodies post-vaccination using the FDA EUA MidaSpot™ Antibody Combo Detection Kit 41 . Finally, for comparison we determined anti-RBD IgG and anti-NCP antibody levels in a cohort of healthy volunteers from the pre-pandemic era and from patients hospitalized with COVID-19.

Between January and May 2021, a total of 71 adults vaccinated with Pfizer (n = 54) and Moderna (n = 17) were recruited for this study including Caucasians (63.4%), Asians (29.6%), and African Americans (7.0%), with a mean age of 46.8 ± 13.1 years. The common comorbidities reported were hypertension (16.9%), hyperlipidemia (8.5%), autoimmune type disorders (4.2%), and diabetes (1.4%) (Supplementary Table S1 ).

Post-vaccination local reaction and systemic events are included in Table 1 . Myalgia, malaise, headaches, and fever were the most common symptoms, with increased frequency and severity after the second dose. After the first and second doses, respectively, 44% and 27% of subjects reported mild-to-moderate pain at the injection site. 60% of participants experienced mild-tomoderate systemic symptoms. Compared to participants who received the Pfizer vaccine, those who received the Moderna vaccine exhibited higher symptom frequency (78% vs. 55%) and severity for the 1 st and 2 nd vaccine dose (Figure 4c ). One study subject receiving the Moderna . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint vaccine reported syncope and vertigo, requiring a short hospitalization. Symptoms generally peaked at two days after vaccination and resolved within a week. No subjects experienced recurring symptoms or contracted COVID-19 after the second dose.

To investigate the immune response to SARS-CoV-2 mRNA vaccines, we measured pre-first dose (day 0) and vaccine-elicited anti-RBD IgG antibodies at various times post-vaccination in 71 vaccinees between 19 and 146 days following the first vaccine dose. Based on the days from first-dose injection, vaccinated samples were divided into five groups: D0 (0 days, prior to first Rapid testing was performed as a preliminary qualitative detection of antibodies elicited by vaccination with a 10 μL fingerstick sample, meanwhile a 10 μL DBS sample was saved for quantitative pGOLD™ assay. The POC MidaSpot™ lateral flow assay detected anti-RBD IgG in ~ 90% of vaccinees after the first dose (Table 2, Figure 1 ) and 100% positive rate in fully vaccinated individuals at day 33-55 for both the Moderna and Pfizer cohorts. With ~ 10% vaccinees, MidaSpot detected low or negative IgG signals after the first dose but detected clear IgG lines after the second dose (Figure 1a, 1c) . The negative agreement is 100% for both vaccines in the pre-vaccination group (Table 2) .

Using the pGOLD™ assay, we detected anti-RBD IgG with a 100% positive rate for all vaccinees at all the post-first dose timepoints (D19-28, D33-55, D61-83, D89-108, and D112-146), and a 100% negative rate in the pre-vaccination group (D0), as well as pre-pandemic samples. Since the mRNA vaccines encode the SARS-CoV-2 spike protein, the pGOLD™ assay only detected positive anti-RBD for the vaccinees without detecting anti-NCP IgG (Figure 2a, 2c, 2d), compared to both positive anti-RBD and anti-NCP detected in COVID-19 patients ( Figure 2b, 2e, 2f) . It was also observed that there was a clear increase in baseline signals for anti-NCP IgG after the D33-55 timepoint, but still below the cutoff value of 10.3 ( Figure 2d ).

However, the reason is unknown.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint

The quantitative pGOLD™ assay data showed an anti-RBD IgG peaking and then declining trend in all vaccinated subjects (Figure 2c ). The anti-RBD antibodies evolved from a low baseline level (D0), upward to mildly positive (D19-28), rapidly peaking (D33-55), and then gradually decreasing (D61-83, D89-108, D112-146) (Figure 2c ). Each group's general data information is summarized in Supplementary Table S2 . The normality test by the Shapiro-Wilk method showed that the anti-RBD IgG levels grouped by time points were non-normal for D0, D19-28, D33-55, D61-83, and D112-146, and normal for D89-108 (Supplemental Table S3 ). It is to be noted that the D89-108 timepoint only had 15 samples. We then used a nonparametric statistical analysis method, the Mann-Whitney test (Supplementary Table S4 Table S4 ). The anti-RBD IgG levels measured at 19-28 days (D19-28 group), before the second dose, were significantly lower than the later groups (D33-55, D61-83, D89-108, and D112-146) with p value < 0.0001, respectively (Supplementary Table S4 Table S4 ).

A SARS-CoV-2 anti-RBD IgG avidity assay was developed on Nirmidas' pGOLD™ platform to investigate antibody-antigen binding strength and stability under denaturing conditions. In the pGOLD™ anti-RBD IgG avidity test, a 4 M urea-containing sample buffer and urea-free normal sample buffer were employed to dilute the same sample solution derived from a vaccinee's DBS, then loaded into neighboring wells on pGOLD™ biochips for detecting anti-RBD IgG with and without urea treatment (Figure 3a) . A higher avidity index (the ratio of IgG level with urea . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint treatment over that without urea treatment) indicated that the detected antibody possessed a stronger and more stable binding to the antigens on pGOLD™ against denaturing forces.

Averaged over all participants in the two mRNA vaccinated cohorts, we observed that the anti-RBD IgG avidity showed a generally increasing trend with time ( Figure We also observed that 100% of the Moderna cohort of vaccinees tested positive by the qualitative MidaSpot™ rapid test after receiving the first dose through the four-month period of monitoring (Table 2) . On the other hand, 5.4% of the Pfizer vaccinees turned negative by rapid test greater than three months after the first dose. Close comparison with quantitative pGOLD™ antibody data showed that the anti-RBD levels in these 'negative' samples were still above the cutoff value relative to the pre-vaccination level but were indeed close to the minimum levels of the corresponding groups of the cohort, and at least three-fold lower than the median levels . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint

The SARS-CoV-2 spike protein is a homo-trimeric glycoprotein containing the receptor binding domain (RBD), which mediates virus infection to host cells by interacting with its receptor: human angiotensin converting enzyme 2 (ACE-2) on the cell surface 19 consuming, making them difficult to implement in a large vaccinated population. Importantly, there has been accumulating evidence that anti-spike/RBD IgG levels are strongly correlated with neutralizing activity in COVID-19 patients 26-30 and vaccinated individuals 44 . It is reasonable that anti-RBD IgG levels are measured to assess neutralizing antibody levels, which could be done quantitatively in many laboratories or qualitatively at POC sites. In this study, we focused on measuring anti-RBD IgG levels and anti-RBD IgG avidity to investigate the kinetics and maturation of vaccine-elicited antibodies.

One of our findings was that both the Pfizer and Moderna mRNA vaccines elicited anti-RBD IgG effectively in 100% of the 71 vaccinees studied longitudinally. The average IgG levels were boosted by the second dose and peaked after ~ two weeks. Antibody levels then showed a downward trend up to the four-month timepoint. These observations were similar to recent reports on the Pfizer and Moderna vaccines 5,15,45 . Comparing these two cohorts side-by-side . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint revealed that the average antibody levels in the Moderna cohort in the first three months postvaccination were higher than in the Pfizer cohort, consistent with the more severe, but mostly tolerated side effects (with only one hospitalization in the Moderna cohort). However, at the four-month timepoint, anti-RBD IgG levels in the Moderna and Pfizer cohorts were closer, suggesting potentially similar long-term effects and vaccine efficacy.

The antibody avidity index provides an assessment of antibody-antigen binding strength by measuring antibodies specifically bound to antigens in the presence of a denaturing agent. It is known that the antibodies produced in the early days of an infection show low avidity with weak binding to the viral antigen. Avidity increases as antibodies mature over months or years through processes including colonial expansion, hypermutation, and affinity selection in the germinal center 46 . Antibody avidity has been used to assess recent vs. remote infections 18,35-39 and to analyze vaccination efficacy, immunity, and the success of convalescent plasma-based antibody therapy [47] [48] [49] .

Overall, the average avidity index of the two mRNA vaccines showed an increasing trend over the four months period monitored ( Figure 3b ). Consistent with a stronger immune response, the average anti-RBD IgG avidity for the Moderna cohort was higher than that of the Pfizer cohort but did not show an obvious upward trend in the 4-month period. In contrast, anti-RBD IgG in the Pfizer cohort showed a steady increase approaching that of the Moderna cohort, suggesting a clear antibody maturation process. In the four-month post-vaccination timepoint (Figure 4a, 4b) , the two mRNA vaccines were associated with similar antibody levels and avidity (slightly higher for Moderna), consistent with the similar ~ 95-98% efficacy (also slightly higher for Moderna) in protection from COVID-19 infection from clinical trials.

Both antibody concentration/quantity and antigen binding strength/avidity are important to immunity and can be used to analyze vaccine effectiveness. As antibody concentration wanes over time post-vaccination, a higher avidity could be important to sustain immunity and maintain the ability to fight viral infection at reduced antibody levels. We clearly observed increasing anti-RBD avidity and maturation with the Pfizer vaccinee cohort (Figure 4b ), a welcoming result since even though the antibody concentration decreased over time, the viral-antigen binding strength increased for the remaining antibodies. The Moderna vaccinee cohort showed high antibody levels and avidity in the first 4 months period with more severe side-effects, without an obvious increase in avidity. The differences between the two mRNA vaccines were interesting . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint but not understood currently. Clearly, it is important to continue monitoring the two cohorts over longer periods of time to investigate further evolutions of antibody levels and avidity and their relations to immunity. It is possible that antibody maturation continues to further boost avidity and afford useful viral fighting capabilities even at low antibody levels.

We observed that women and subjects < 50 years of age tended to exhibit a better immune response, and subjects with a history of autoimmunity had a lower immune response. By oneway ANOVA analysis, we analyzed subjects that were ≤ 50 years and > 50 years of age. Anti-RBD IgG was significantly higher at the three-to four-months measurement point (75.5±49.2 vs. 48 .5±34.0, p=0.047). We analyzed subjects who had autoimmunity (n = 4) and found that the anti-RBD IgG levels were significantly lower at the three-to four-months point compared to the rest of the group (n = 40) (75.5±49.2 vs 48.5±34.0, p=0.045).

We performed the MidaSpot™ POC rapid antibody test as an initial qualitative assessment of immune response to vaccination, during which dried blood spots were collected for quantitative pGOLD™ assay. The results also shed light on whether rapid antibody tests could be used to produce meaningful frontline assessment of antibody levels elicited by the vaccines at POC sites.

Importantly, the FDA EUA MidaSpot™ rapid antibody test detected anti-RBD IgG with 100% sensitivity in fully mRNA vaccinated subjects (~ two weeks after the second dose). For the Moderna vaccinees, 100% antibody positivity persisted to the ~ four-month timepoint, with ~ 94% positivity for the Pfizer cohort. Importantly, the 5.4% negative results were from the threeto four-month timepoints, for vaccinees whose quantitative anti-RBD levels measured by pGOLD™ were close to minimum levels of the corresponding groups of the cohort, and at least three-fold lower than the median values (Table 2, Supplementary Table S5 ). We conclude that the MidaSpot™ rapid test can indeed provide a useful qualitative, preliminary assessment of immune response to vaccination. For subjects whose MidaSpot™ rapid test anti-RBD result turned negative or very faint in the signal line, the corresponding quantitative antibody level was low and warranted further testing or clinical decisions.

The pGOLD™ assay is a novel nanotechnology assay platform capable of quantifying antibody levels and binding affinity to viruses 18,39,50-52 . It is also capable of detecting antibodies in DBS or saliva samples and could offer a non-invasive approach to assess antibody response to vaccination. Furthermore, the combination of the MidaSpot™ rapid antibody test and the . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; 1 0 pGOLD™ assay could generate more complete information on vaccine-elicited antibody levels by quantity and quality with time.

Limitations of our current study include the small sample size that is unequal among groups, missing data at some timepoints, and the limited population diversity.

In summary, we performed a longitudinal study of two prominent mRNA vaccines for SARS-CoV-2 by rapid antibody testing and quantitative measurements of antibody levels and binding strength based on the avidity index. The 4-months post-vaccination results are presented here as an interim report, and the study will continue up to more than a year. Thus far, both vaccines elicit similar levels of anti-RBD IgG and avidity at the 4-month timepoint, suggesting that both vaccines are similarly efficient at protecting vaccinated populations. We compared the two mRNA vaccinee groups and observed interesting differences, and the results might shed light on vaccine development. An ideal vaccine would be one that generates not only high antibody levels, but also high viral-antigen binding strength, and at the same time affords well-tolerated side effect severity. With the vaccinees, we observed that in general, although antibody levels decreased over time, antibody maturation was observed with increased antigen binding strength, boding well for sustained immunity. We did observe highly variable immune responses including those with well below average anti-RBD IgG levels and avidity. It is therefore important to monitor immune responses at the individualized and personalized level, identify those who are still at risk even after vaccination, and provide meaningful measures to protect them from infections.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint

The study (NCT# 04910971) was performed in accordance with standard ethical principles and approved by the LifeBridge Health local Institutional Review Board under Protocol # 1707882. All participants provided written consent. Subjects 

Nirmidas' MidaSpot™ COVID-19 Rapid Antibody Combo Detection Kit was used for initial screening and assessment of immune response (Figure 1 ). This test was approved by the United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for POC testing, ideally suited for qualitative antibody testing at any healthcare site. The lateral flow assay detected both immunoglobulins IgG and IgM against the SARS-CoV-2 viral spike protein receptor-binding domain (RBD), which is the same antigen expressed by the mRNA vaccines. In addition, a dry blood spot card for each subject taken at each timepoint was stored at -20 º C, batched, and shipped to Nirmidas Biotech Inc. (Palo Alto, CA, USA) to perform the pGOLD™ COVID-19 High Accuracy IgG/IgM Assay to quantify antibody levels and avidity as previously described, with minor modifications 18 . Briefly, we conjugated iFluor TM 820 succinimidyl ester (ATT Bioquest, Cat. No:1399) and CF647 succinimidyl ester (Millipore Sigma, SCJ4600048) to anti-human IgG and anti-human IgM, respectively. The iFluor TM 820-labeled anti-human IgG and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint CF647-labeled anti-human IgM were used for two-color simultaneous multiplexed detection of IgG and IgM against RBD and nucleocapsid protein (NCP) antigens printed on pGOLD™ slides using a robotic micro-arrayer.

A 2 mm circle was punched out from each DBS card (comprised of 10 μL of fingerstick whole blood drop, dried on the card) and dissolved into 160 µL sample solution containing 10% fetal bovine serum (FBS), 0.05% Tween 20 and 0.1% NaN 3 in 1X phosphate-buffered saline (PBS) under 1 hour shaking at room temperature. After a brief centrifugation, the DBS-dissolved sample solution was heated for 30 minutes at 56 º C. The heat-inactivated solution was used for the pGOLD™ assay immediately or stored at 4 º C for later use.

The pGOLD™ antibody assays were performed in a 64-well format in the following steps. 1)

Blocking: All wells were blocked with a blocking buffer containing 2% bovine serum albumin (BSA) in 1X PBS for 30 minutes at room temperature; 2) Sample incubation: each well was then incubated with 100 µL of 2X diluted dissolved DBS sample solution in 10% FBST (10% FBS including 0.05% Tween 20) for 60 minutes at room temperature. A mixture of diluted anti-RBD IgG/IgM purified antibodies as signal normalizer was loaded into the neighboring well on the same row as each sample tested, and a blank control (10% FBST only) was included on each biochip; 3) Secondary antibody incubation: each well was subsequently incubated with a mixture of 4 nM iFluor TM 820-labeled anti-human IgG secondary antibody, 4 nM CF647-labeled antihuman IgM secondary antibody, and 4 nM iFluor TM 820-labeled streptavidin in a 2% BSA solution for 30 minutes at room temperature. Each well was washed six times with 1X PBST (10X PBST: 10X PBS with 0.5% Tween 20) between steps. The iFluor TM 820-labeled streptavidin in the detection step binds to BSA-biotin spots in each well on the pGOLD™ biochip, and the signal was used as an "intrawell signal normalizer". In parallel, row-dependent, antigen-specific "adjacent well" normalization was performed to normalize antigen printing variation or slide-to-slide variation. Anti-RBD IgG/IgM levels were calculated as the ratio of anti-RBD signal of the sample to that of the adjacent well normalizer and multiplied by 100.

Anti-NCP IgG levels were calculated as the ratio of anti-NCP signal of the sample to that of the intrawell normalizer (BSA-Biotin) multiplied by 100.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint pGOLD™ IgG avidity assay

The pGOLD™ IgG avidity index was measured by detecting anti-RBD IgG signals in a dissolved DBS sample in 10% FBST, with and without 4 M urea, respectively. The two solutions were run side-by-side in neighboring pGOLD™ wells, under the otherwise identical pGOLD™

protocol. An avidity index was calculated as the ratio of IgG signal detected in the solution with 4 M urea to that without urea 53 . Avidity is always below the value of 1, since the denaturing urea tends to weaken antibody binding to antigens immobilized on pGOLD™. A higher avidity index corresponds to higher antibody-antigen binding strength. 

Continuous values were shown as mean ± standard deviation for normally distributed data and median and interquartile range (IQR) for nonparametric data. The Shapiro Wilk test was used to determine the normality of anti-RBD IgG levels in each group (COVID-19, pre-pandemic, prevaccination D0, D19-28 prior to the second dose, D33-55, D61-83, D89-108, and D112-146).

The Mann-Whitney U test was performed to compare anti-RBD IgG levels between two groups for non-parametrically distributed data. A p value < 0.05 was considered statistically different between two groups (COVID-19, pre-vaccination D0, D19-28, D33-55, D61-83, D89-108, and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 2, 2021. Table S2 . Data summary of anti-RBD IgG levels in each group. The SARS-CoV-2 infected group refers to individuals who provided DBS samples for analysis of anti-RBD and anti-NCP IgG levels after symptom onset and after confirmatory tests were conducted. D0 is the group of individuals who provided DBS samples one day prior to their first dose of vaccine. D19-28, D33-55, D61-83, D89-108, and D112-146 refer to the timepoints at which the vaccinated study participants provided samples for analysis. The prepandemic data are from serum samples collected prior to November 2019. Minimum, Q1, median, Q3, and maximum IgG Levels refer to the pGOLD™ anti-RBD results obtained after performing analysis of the samples from each of these groups. Testing was performed at Nirmidas Biotech, Inc. in Palo Alto, California. Statistical analysis was performed using OriginPro 2021b.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. Table S4 . Comparison of Anti-RBD IgG levels between groups by the Mann-Whitney Test. Comparing anti-RBD IgG levels between different groups by the Mann-Whitney test indicated the similarity between groups, according to the asymptotic probability values. р > 0.05 indicates similarity between two groups; Otherwise, р < 0.05 indicates a clear difference between two groups with statistical significance. Statistical analysis was performed using OriginPro 2021b.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 2, 2021. ; https://doi.org/10.1101/2021.06.28.21259338 doi: medRxiv preprint

Are IgG antibody avidity assays useful in the diagnosis of infectious diseases? A review

Precision and Accuracy of a Procedure for Detecting Recent Human Immunodeficiency Virus Infections by Calculating the Antibody Avidity Index by an Automated Immunoassay-Based Method

Diagnosis and Outcome of Preconceptional and Periconceptional Primary Human Cytomegalovirus Infections

Use of an Immunoglobulin G Avidity Test To Discriminate between Primary and Secondary Dengue Virus Infections

Diagnosis of Zika virus infection on a nanotechnology platform

Recent rubella virus infection indicated by a low avidity of specific IgG

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy

Convalescent serum lines up as first-choice treatment for coronavirus

A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes

Multiplexed Anti-Toxoplasma IgG, IgM, and IgA Assay on Plasmonic Gold Chips: towards Making Mass Screening Possible with Dye Test Precision

Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision

this study

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Urea dilution of serum for reproducible anti-HSV1 IgG avidity index

This work was supported by Nirmidas Biotech, Inc. internal R&D funds, and by Platelet and Thrombosis Research, LLC, Baltimore, MD, USA. Tables, and manuscript drafts. J.H., S.Z., and D.Y.S. collected, prepared samples, and performed data analysis. U.S.T and K.P.B were involved in study design, laboratory processing, data collection, statistical analysis, and manuscript preparation. A.R., N.R., and N.W. were involved in patient recruitment and data collection. R.C. and R.E. were involved in study design and manuscript preparation.All authors commented on the manuscript.

Dr. Gurbel reports grants and personal fees from Bayer HealthCare LLC, Otitopic Inc, Amgen, Janssen, and US WorldMeds LLC; grants from Instrumentation Laboratory, Haemonetics, Medicure Inc, Idorsia Pharmaceuticals, and Hikari Dx; personal fees from UpToDate; Dr Gurbel